Skip to content

Person-checked company records fromPerson-checked records $750See a worked exampleHuman review in progress

Talk to sales

KeptIndex

Amgen Inc.

Report initial data from Phase 2 monotherapy study in patients with advanced NSCLC

Delivered by the deadline

AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.

Announced
30 Apr 2020
Due
31 Dec 2020
Delivered
October 2020
  • Deadline
  • Met
  • Late
  • Not met
  • Today

What the company said

“The Company reiterated its expectation of initial data in 2020 from a potentially pivotal Phase 2 monotherapy study in patients with advanced NSCLC”

What we found

Evidence strength A What the grades mean

Amgen announced top-line Phase 2 results for its KRAS G12C-mutant advanced NSCLC study in October 2020, meeting the commitment to report initial data within the 2020 calendar year.

  • A
    Amgen Inc. 10-K filed 2021-02-09 Regulatory filing · published 9 Feb 2021 · retrieved 1 Oct 2026 · kept permanently by the SEC
    “In October 2020, we announced top-line phase 2 results in 126 patients with KRAS G12C-mutant advanced NSCLC.” ✓ confirmed on the page

Market reaction: the shares moved -0.4% against the S&P 500 over the three sessions around the disclosure (8 Feb 2021 to 11 Feb 2021). What this measures

Checked 1 Oct 2026.

Commitment DNA

The structured record of this commitment. Fields the company did not state are left blank rather than guessed.

Event type
Clinical readout
Indicative materiality
Medium rules
Action
Report
Deliverable
Phase 2 study data
In the company’s control
High
Specificity
Medium

How this entry was checked

  1. Commitment recordedThe company's words were matched word for word against the filing.
  2. First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
  3. Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.

Confirmed. This outcome counts towards the company's Kept Score. How verification works

Are you Amgen Inc.? You can publish an official statement next to this entry, free. Add a statement.

Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.

Report an error in this entry Reference: KI-C-2020-AMGN-002319 · Corrections policy

The Deadline Report

One email a week: the corporate commitments that came due, which were met, which slipped, and what is due next. Free. Stop any time.

No advertising. We never sell or share your address.